Prediction of Cancer Drug Resistance and Implications for Personalized Medicine.

Drug resistance still impedes successful cancer chemotherapy. A major goal of early concepts in individualized therapy was to develop in vitro tests to predict tumors’ drug responsiveness. We have developed an in vitro short-term test based on nucleic acid precursor incorporation to determine clinic...

Full description

Bibliographic Details
Main Authors: Manfred eVolm, Thomas eEfferth
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-12-01
Series:Frontiers in Oncology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00282/full
id doaj-8a3b77ec215b4c01bd481befeb283b09
record_format Article
spelling doaj-8a3b77ec215b4c01bd481befeb283b092020-11-24T22:35:55ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2015-12-01510.3389/fonc.2015.00282166200Prediction of Cancer Drug Resistance and Implications for Personalized Medicine.Manfred eVolm0Thomas eEfferth1German Cancer Research CenterUniversity of MainzDrug resistance still impedes successful cancer chemotherapy. A major goal of early concepts in individualized therapy was to develop in vitro tests to predict tumors’ drug responsiveness. We have developed an in vitro short-term test based on nucleic acid precursor incorporation to determine clinical drug resistance. This test detects inherent and acquired resistance in vitro and transplantable syngeneic and xenografted tumors in vivo. In several clinical trials, clinical resistance was predictable with more than 90% accuracy, while drug sensitivity was detected with less accuracy (~60%). Remarkably, clinical cross-resistance to numerous drugs (multidrug-resistance, broad spectrum resistance) was detectable by a single compound, doxorubicin, due to its multifactorial modes of action. The results of our predictive test were in good agreement with predictive assays of other authors. As no predictive test has been established as yet for clinical diagnostics, the identification of sensitive drugs may not reach sufficiently high reliability for clinical routine. We propose a rethinking of the chemosensitivity concept. Instead, predictive in vitro tests may reliably identify drug-resistant tumors. The clinical consequence imply to subject resistant tumors not to chemotherapy, but to other new treatment options such as antibody therapy, adoptive immune therapy, hyperthermia, gene therapy etc. The high accuracy to predict resistant tumors may be exploited to develop new strategies for individualized cancer therapy. This new concept bears the potential of a revival of predictive tests for personalized medicine.http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00282/fullDrug Resistancechemotherapyindividualized therapypersonalize medicineSurvival times
collection DOAJ
language English
format Article
sources DOAJ
author Manfred eVolm
Thomas eEfferth
spellingShingle Manfred eVolm
Thomas eEfferth
Prediction of Cancer Drug Resistance and Implications for Personalized Medicine.
Frontiers in Oncology
Drug Resistance
chemotherapy
individualized therapy
personalize medicine
Survival times
author_facet Manfred eVolm
Thomas eEfferth
author_sort Manfred eVolm
title Prediction of Cancer Drug Resistance and Implications for Personalized Medicine.
title_short Prediction of Cancer Drug Resistance and Implications for Personalized Medicine.
title_full Prediction of Cancer Drug Resistance and Implications for Personalized Medicine.
title_fullStr Prediction of Cancer Drug Resistance and Implications for Personalized Medicine.
title_full_unstemmed Prediction of Cancer Drug Resistance and Implications for Personalized Medicine.
title_sort prediction of cancer drug resistance and implications for personalized medicine.
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2015-12-01
description Drug resistance still impedes successful cancer chemotherapy. A major goal of early concepts in individualized therapy was to develop in vitro tests to predict tumors’ drug responsiveness. We have developed an in vitro short-term test based on nucleic acid precursor incorporation to determine clinical drug resistance. This test detects inherent and acquired resistance in vitro and transplantable syngeneic and xenografted tumors in vivo. In several clinical trials, clinical resistance was predictable with more than 90% accuracy, while drug sensitivity was detected with less accuracy (~60%). Remarkably, clinical cross-resistance to numerous drugs (multidrug-resistance, broad spectrum resistance) was detectable by a single compound, doxorubicin, due to its multifactorial modes of action. The results of our predictive test were in good agreement with predictive assays of other authors. As no predictive test has been established as yet for clinical diagnostics, the identification of sensitive drugs may not reach sufficiently high reliability for clinical routine. We propose a rethinking of the chemosensitivity concept. Instead, predictive in vitro tests may reliably identify drug-resistant tumors. The clinical consequence imply to subject resistant tumors not to chemotherapy, but to other new treatment options such as antibody therapy, adoptive immune therapy, hyperthermia, gene therapy etc. The high accuracy to predict resistant tumors may be exploited to develop new strategies for individualized cancer therapy. This new concept bears the potential of a revival of predictive tests for personalized medicine.
topic Drug Resistance
chemotherapy
individualized therapy
personalize medicine
Survival times
url http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00282/full
work_keys_str_mv AT manfredevolm predictionofcancerdrugresistanceandimplicationsforpersonalizedmedicine
AT thomaseefferth predictionofcancerdrugresistanceandimplicationsforpersonalizedmedicine
_version_ 1725722237978279936